Comprehensive Study Notes on Glycogen Metabolism and Related Disorders

Course Information

Faculty: Faculty of Pharmacy, PharmD Clinical Program
Course: Biochemistry II ( $PBC202$ )
Term: Spring 2026
Level: 2
Lecturer: Dr. Sherif Adel Elsabbagh, Lecturer of Biochemistry
Institution: Galala University (GU) — Powered by Arizona State University

Overview of Glycogen Metabolism

Rationale for Glycogen Storage: * Dietary Intake: This source is sporadic and unreliable, as it is heavily dependent on the timing and composition of meals. It cannot guarantee a constant supply of blood glucose between meals. * Gluconeogenesis: While this process provides sustained glucose synthesis from non-carbohydrate precursors (lactate, glycerol, and amino acids), it is slow to ramp up when blood glucose levels first begin to decline. * Glycogen Degradation: This provides rapid mobilization. Liver glycogen can release free glucose into the blood within minutes, acting as a critical bridge until gluconeogenesis can take over.
Clinical Duration: * Liver glycogen stores are typically sufficient to maintain blood glucose levels for less than $24$ hours during fasting. Once these stores are depleted, gluconeogenesis becomes the primary source of glucose. * Tissue Specificity: Muscle glycogen serves only local energy needs and cannot contribute to systemic blood glucose.

Structure and Architecture of Glycogen

Chemical Composition: Glycogen is a branched-chain polysaccharide made exclusively from $\alpha\text{-D-glucose}$ .
Linkage Types: * Primary Backbone: Constructed via $\alpha(1\rightarrow4)$ glycosidic bonds that form the linear chain of glucosyl residues. * Branch Points: Formed via $\alpha(1\rightarrow6)$ glycosidic bonds occurring every $8-14$ residues.
Molecular Size: A single glycogen molecule consists of a polymer of up to $55,000$ glucose residues.
Storage Form: It is stored as large, spherical cytoplasmic granules that reside alongside the enzymes responsible for its synthesis and degradation.
Functional Significance of Branching: * Solubility: Branching dramatically increases the solubility of the polymer. * Multiple Nonreducing Ends: Branching creates many nonreducing ends. This allows glycogen phosphorylase and glycogen synthase to work simultaneously at many different sites, thereby accelerating the rates of both synthesis and degradation.

Comparison of Liver and Muscle Glycogen

Liver Glycogen: * Amount: Approximately $100\,g$ , which constitutes up to $10\%$ of the liver's fresh weight. * Function: Maintenance of blood glucose levels, particularly during the early stages of fasting. * Glucose 6-Phosphatase: Present in the Endoplasmic Reticulum (ER). It dephosphorylates Glucose 6-Phosphate ( $G6P$ ) to release free glucose into the blood. * Response to States: Replenished in the well-fed state by insulin; depleted during fasting. * Clinical Correlation: $GSD$ Type I (Von Gierke Disease) involves a deficiency in $G6Pase$ , leading to severe fasting hypoglycemia.
Muscle Glycogen: * Amount: Approximately $400\,g$ , constituting $1-2\%$ of resting muscle weight. Note that the total body mass of muscle glycogen exceeds that of the liver due to the total volume of muscle tissue. * Function: Local fuel source for ATP synthesis used during muscle contraction. * Glucose 6-Phosphatase: Absent. Therefore, muscle glucose 6-phosphate cannot be released into the blood. * Response to States: Rapidly depleted during strenuous exercise and replenished at rest. It is not significantly affected by short-term fasting (lasting a few days). * Clinical Correlation: $GSD$ Type V (McArdle Disease) involves a muscle phosphorylase deficiency, resulting in exercise intolerance and a lack of lactate rise during exertion.

Glycogenesis (Glycogen Synthesis)

Location: Occurs in the cytosol.
Energy Requirement: Requires $1$ ATP per glucose (via Hexokinase/Glucokinase) and $1$ UTP per glucose (via UDP-glucose pyrophosphorylase).
Step 1: Glucose Activation to UDP-Glucose: * Hexokinase / Glucokinase: Phosphorylates Glucose using ATP to create Glucose 6-phosphate, trapping it in the cell. Glucokinase (liver) has a high $K_m$ (low affinity) and operates only when glucose is abundant. * Phosphoglucomutase: Converts Glucose 6-phosphate to Glucose 1-phosphate. This is a reversible reaction that requires Glucose 1,6-bisphosphate as an obligatory intermediate. * UDP-glucose Pyrophosphorylase: Combines Glucose 1-phosphate and UTP to form UDP-glucose (the activated building block) and Pyrophosphate ( $PP_i$ ). * Pyrophosphatase: Immediately hydrolyzes $PP_i$ into $2\,P_i$ , which makes the previous reaction irreversible and drives the production of UDP-glucose.
Step 2: Primer Synthesis and Chain Elongation: * Primer Necessity: Glycogen synthase cannot start a new chain on free glucose; it requires an existing chain of $\ge 4$ glucose residues. * Glycogenin: A homodimeric protein acting as both the acceptor and the enzyme. It autoglucosylates its own Tyrosine-194 ( $Tyr-194$ ) hydroxyl group using UDP-glucose. It adds $\ge 4$ glucose residues to create the primer and remains at the core of the granule. * Glycogen Synthase: Transfers glucose from UDP-glucose to the nonreducing end of the growing chain, forming a new $\alpha(1\rightarrow4)$ glycosidic bond (attaching the anomeric $C1$ of the new glucose to the $C4$ of the terminal residue). This releases UDP. * UDP Recycling: UDP is rephosphorylated to UTP by nucleoside diphosphate kinase ( $UDP + ATP \rightarrow UTP + ADP$ ).
Step 3: Branch Formation: * Branching Enzyme: Formally known as Amylo- $\alpha(1\rightarrow4)\rightarrow\alpha(1\rightarrow6)$ -Transglycosylase (or 4:6 Transferase). * Mechanism: It removes a terminal block of $6-8$ glucosyl residues from a nonreducing end (breaking an $\alpha(1\rightarrow4)$ bond) and reattaches them to a non-terminal glucose via a new $\alpha(1\rightarrow6)$ bond. * Result: This creates two nonreducing ends where only one existed before, allowing for exponential acceleration of synthesis. * Clinical Note (Andersen Disease - GSD IV): Deficiency in branching enzyme leads to glycogen with very long, unbranched chains (similar to plant amylose). This is poorly soluble, triggers a foreign body response, and often leads to fatal hepatic cirrhosis by age 5. It is the only $GSD$ of synthesis.

Glycogenolysis (Glycogen Degradation)

General Principle: Glycogenolysis is a separate cytosolic pathway, not a reversal of synthesis. The primary product is Glucose 1-phosphate, not free glucose.
Step 1: Chain Shortening by Glycogen Phosphorylase: * Process: Cleaves $\alpha(1\rightarrow4)$ bonds at nonreducing ends via Phosphorolysis. It uses inorganic phosphate ( $P_i$ ) rather than water to release Glucose 1-phosphate. * Efficiency: Using $P_i$ instead of water saves the cell the ATP cost of re-phosphorylating glucose, as the product is already "primed." * Coenzyme: Requires Pyridoxal Phosphate ( $PLP$ ), a derivative of Vitamin $B_6$ , which is covalently bound and acts as a proton donor/acceptor. * Limit Dextrin: Phosphorylase stops cleaving residues when it gets within $4$ residues of an $\alpha(1\rightarrow6)$ branch point due to steric constraints. This resulting structure is the limit dextrin.
Step 2: Branch Removal by Debranching Enzyme: * Nature of the Enzyme: A single bifunctional protein with two distinct catalytic activities. * Activity 1 (4:4 Transferase): Moves the outer $3$ of the remaining $4$ branch-point glucosyl residues to the nonreducing end of another chain (breaking one $\alpha(1\rightarrow4)$ and making a new $\alpha(1\rightarrow4)$ ). * Activity 2 (Amylo-\alpha(1\rightarrow6)-Glucosidase): Hydrolyzes the single remaining glucose residue attached at the $\alpha(1\rightarrow6)$ linkage. This step releases FREE (unphosphorylated) glucose. This is the only step in glycogenolysis that produces free glucose.
Fate of Glucose 1-Phosphate: * In Liver: $G1P \rightarrow G6P$ (via phosphoglucomutase). $G6P$ is moved into the ER by a translocase, where Glucose 6-phosphatase removes the phosphate. Free glucose exits the hepatocyte into the bloodstream. * In Muscle: $G1P \rightarrow G6P$ (via phosphoglucomutase). $G6P$ directly enters glycolysis to produce ATP for muscle contraction. Muscle lacks Glucose 6-phosphatase and cannot contribute to blood glucose.

Lysosomal Degradation and Pompe Disease

Minor Pathway: Approximately $1-3\%$ of total glycogen is degraded in lysosomes via autophagy.
Enzyme: Acid $\alpha(1\rightarrow4)$ -glucosidase (also called acid maltase). It hydrolyzes both $\alpha(1\rightarrow4)$ and $\alpha(1\rightarrow6)$ bonds at an acidic $pH$ .
GSD Type II (Pompe Disease): * Mechanism: Acid maltase deficiency leads to glycogen accumulation in lysosomes across many tissues (heart, muscle, liver, CNS). * Classification: The only $GSD$ classified as a Lysosomal Storage Disease. * Symptoms: Massive cardiomegaly, profound hypotonia ("floppy baby"), and respiratory failure. Blood glucose levels remain NORMAL because the cytoplasmic pathway is intact. * Treatment: Enzyme replacement therapy with alglucosidase alfa (Myozyme).

Regulation of Glycogen Metabolism

Covalent Regulation (Hormonal / cAMP Cascade): * Trigger: Glucagon (liver) or Epinephrine (liver and muscle) binds to a G-Protein Coupled Receptor ( $GPCR$ ). * Cascade: $G\text{-protein} \rightarrow \text{Adenylyl Cyclase} \rightarrow cAMP \uparrow \rightarrow \text{Protein Kinase A (PKA)}$ . * PKA Action: PKA phosphorylates Phosphorylase Kinase (activating it). Active Phosphorylase Kinase phosphorylates Glycogen Phosphorylase (activating it, form 'a'). Simultaneously, PKA phosphorylates Glycogen Synthase (inactivating it, form 'b'). * Amplification: A few hormone molecules lead to many active enzymes. * Inactivation: Insulin activates Phosphodiesterase (degrades $cAMP$ ) and Protein Phosphatase-1 ( $PP1$ ), which removes phosphate groups to restore inactive forms of phosphorylase and active forms of synthase.
Allosteric Regulation (Local Metabolites): * Glucose 6-Phosphate: Activates glycogen synthase; inhibits glycogen phosphorylase. * ATP: Inhibits glycogen phosphorylase (high energy state). * AMP: Activates glycogen phosphorylase in muscle during low energy states (anoxia/ATP depletion) without needing phosphorylation. * Free Glucose (Liver): Binds to and inhibits phosphorylase 'a', promoting its dephosphorylation.
Role of Calcium ( $Ca^{2+}$ ): * In Muscle: During contraction, $Ca^{2+}$ is released from the sarcoplasmic reticulum. It binds to the Calmodulin ( $CaM$ ) subunit of Phosphorylase Kinase, activating it ALLOSTERICALLY without the need for PKA phosphorylation. This couples contraction directly to energy mobilization. * In Liver: Epinephrine binding to $\alpha_1$ -receptors triggers $Ca^{2+}$ release, activating Phosphorylase Kinase and Protein Kinase C (which inactivates glycogen synthase).

Glycogen Storage Diseases (GSDs)

Type Ia (Von Gierke): Glucose 6-phosphatase deficiency. Severe fasting hypoglycemia, lactic acidemia (lactate cannot enter gluconeogenesis), hyperuricemia (AMP degradation to uric acid), hyperlipidemia, and massive hepatomegaly.
Type II (Pompe): Lysosomal acid $\alpha(1\rightarrow4)$ -glucosidase deficiency. Cardiomegaly and muscle weakness. Normal blood sugar.
Type III (Cori): Debranching enzyme (4:4 transferase/glucosidase) deficiency. Limit dextrin accumulation. Mild hypoglycemia (gluconeogenesis is intact), hepatomegaly, and abnormal glycogen structure.
Type IV (Andersen): Branching enzyme deficiency. Long, unbranched glycogen chains. Hepatic cirrhosis; usually fatal by age 5.
Type V (McArdle): Muscle phosphorylase deficiency. Exercise intolerance, muscle cramps, myoglobinuria, and NO rise in blood lactate during exercise. "Second wind" phenomenon (use of fatty acids/blood glucose) occurs after $10-15$ minutes.
Type VI (Hers): Liver phosphorylase deficiency. Hepatomegaly and mild hypoglycemia. Milder than Type I because gluconeogenesis is intact.
Type VII (Tarui): Muscle Phosphofructokinase ( $PFK-1$ ) deficiency. Similar to McArdle but includes hemolytic anemia because RBCs also lack $PFK$ .

Questions & Discussion

Q1: A patient has severe fasting hypoglycemia, hepatomegaly, and lactic acidemia. Blood glucose does NOT normalize after glucagon injection. Which enzyme is most likely deficient? * Answer: Glucose 6-phosphatase (Von Gierke Disease). Hypoglycemia is severe because both glycogenolysis and gluconeogenesis are blocked from releasing glucose.
Q2: A 6-month-old infant presents with massive cardiomegaly, profound hypotonia, and respiratory distress. Blood glucose is normal. Which organelle is primarily involved in this disease? * Answer: The lysosome (Pompe Disease, deficiency of acid maltase).
Q3: During exercise, $Ca^{2+}$ is released from the sarcoplasmic reticulum. How does this activate glycogenolysis WITHOUT requiring PKA or cAMP? * Answer: $Ca^{2+}$ binds to the calmodulin subunit of phosphorylase kinase, activating it allosterically. This allowed for immediate degradation of glycogen at the start of muscle contraction.
Q4: Glycogen synthase 'b' form is phosphorylated. Is it active or inactive? How does this differ from glycogen phosphorylase? * Answer: Glycogen synthase 'b' is inactive. This is the opposite of glycogen phosphorylase, where the phosphorylated 'a' form is active. This reciprocal control prevents synthesis and degradation from occurring at the same time.
Q5: Why is the fasting hypoglycemia in Hers disease ( $GSD$ VI — liver phosphorylase deficiency) milder than in von Gierke disease ( $GSD$ Ia)? * Answer: In Hers disease, gluconeogenesis is still functional and can provide glucose. In Von Gierke disease, the deficiency in Glucose 6-phosphatase blocks the final common step for both glycogenolysis and gluconeogenesis.
Q6: A young man develops severe muscle cramps during exercise. Blood lactate does NOT rise during a forearm exercise test. Which $GSD$ ? What enzyme is deficient? * Answer: McArdle Disease ( $GSD$ Type V). The deficient enzyme is muscle glycogen phosphorylase (myophosphorylase).